Dr. Chowdhury on Sequencing of Immunotherapy Regimens for RCC

Simon Chowdhury, PhD, MA, MBBS, MRCP
Published: Tuesday, Aug 08, 2017



Simon Chowdhury, PhD, MA, MBBS, MRCP, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses sequencing of immunotherapy regimens for patients with renal cell carcinoma (RCC).

Biomarkers need to be developed to identify which patients will respond to certain treatments, explains Chowdhury. Having more biomarkers will decrease toxicities and costs for patients with RCC.

At the moment, combinations are going to be the way forward since the biomarker research is still in development, states Chowdhury. Clinicians are showing particular interest in immunotherapy in combination with VEGF inhibitors.
 


Simon Chowdhury, PhD, MA, MBBS, MRCP, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses sequencing of immunotherapy regimens for patients with renal cell carcinoma (RCC).

Biomarkers need to be developed to identify which patients will respond to certain treatments, explains Chowdhury. Having more biomarkers will decrease toxicities and costs for patients with RCC.

At the moment, combinations are going to be the way forward since the biomarker research is still in development, states Chowdhury. Clinicians are showing particular interest in immunotherapy in combination with VEGF inhibitors.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x